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Abstract
Background: One of the most common food allergies found in children is cow’s milk allergy. Currently the
only treatment is a strict avoidance diet and to carry self-injectable epinephrine pens. Unfortunately this
current protocol does not prevent against accidental ingestion of cow’s milk protein, which is easily hidden in
many foods and could lead to life threatening allergic reactions. Specific Oral Immunotherapy (OIT) can
allow these children to become desensitized to cow’s milk protein (CMP) and decrease their risk for serious
reactions.
Method: Exhaustive search of available medical literature was conducted using Medline-OVID, CINAHL,
EBMR Multifile, and Web of Science using the keywords: children, immunotherapy and cow’s milk allergy. All
eligible articles that met inclusion criteria were assessed for quality using the Grading of Recommendations,
Assessment, Development and Evaluation (GRADE).
Results: Four articles met inclusion criteria for this systematic review. A randomized control trial, used 60
children with a history of severe allergic reactions to cow’s milk. In the OIT group, 36% of the children
became completely tolerant (daily intake of 150 mL whole milk), 54% were partially tolerant (intake of
5-150mL). All of the children in the treatment group experienced allergic symptoms, 16% required IM
epinephrine. A randomized double-blinded placebo controlled trial, contained 20 children with IgE-mediated
cow’s milk allergy. After OIT the mean cumulative dose causing a reaction was 5 140 mg (240 mL). All the
children in the active group experienced mild to moderate adverse reactions, 25% required IM epinephrine. A
randomized, controlled, single-blinded trial had 30 children randomized into active group (cow’s milk) and
control group (soy milk). Ten of 13 children were able to tolerate 200mL cow’s milk. Two children stopped
the study due to severe allergic reaction. A prospective, observational study, including 105 milk-allergic
children. 81.9% successfully achieved a minimum milk intake of 200 mL a day. 19% failed the protocol due to
severe reactions (12%) or for personal reasons (7%). Multiple adverse reactions occurred during the protocol,
2.8% requiring IM epinephrine. None of the children in each control group became tolerant to cow’s milk and
none required IM epinephrine.
Conclusion: Oral immunotherapy is a promising treatment option for children with cow’s milk allergy.
Before this treatment can be used in clinical practice, further studies are needed to answer remaining issues of
the degree of protection, risk of reactions and best fit protocols.
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Abstract   
 
Background:  One of the most common food allergies found in children is cow’s milk 
allergy. Currently the only treatment is a strict avoidance diet and to carry self-injectable 
epinephrine pens. Unfortunately this current protocol does not prevent against accidental 
ingestion of cow’s milk protein, which is easily hidden in many foods and could lead to 
life threatening allergic reactions. Specific Oral Immunotherapy (OIT) can allow these 
children to become desensitized to cow’s milk protein (CMP) and decrease their risk for 
serious reactions. 
Method:  Exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL, EBMR Multifile, and Web of Science using the keywords: 
children, immunotherapy and cow’s milk allergy. All eligible articles that met inclusion 
criteria were assessed for quality using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE).   
Results: Four articles met inclusion criteria for this systematic review. A randomized 
control trial, used 60 children with a history of severe allergic reactions to cow’s milk. In 
the OIT group, 36% of the children became completely tolerant (daily intake of 150 mL 
whole milk), 54% were partially tolerant (intake of 5-150mL). All of the children in the 
treatment group experienced allergic symptoms, 16% required IM epinephrine. A 
randomized double-blinded placebo controlled trial, contained 20 children with IgE-
mediated cow’s milk allergy. After OIT the mean cumulative dose causing a reaction was 
5 140 mg (240 mL). All the children in the active group experienced mild to moderate 
adverse reactions, 25% required IM epinephrine. A randomized, controlled, single-
blinded trial had 30 children randomized into active group (cow’s milk) and control 
group (soy milk). Ten of 13 children were able to tolerate 200mL cow’s milk. Two 
children stopped the study due to severe allergic reaction. A prospective, observational 
study, including 105 milk-allergic children. 81.9% successfully achieved a minimum 
milk intake of 200 mL a day. 19% failed the protocol due to severe reactions (12%) or for 
personal reasons (7%). Multiple adverse reactions occurred during the protocol, 2.8% 
requiring IM epinephrine. None of the children in each control group became tolerant to 
cow’s milk and none required IM epinephrine.  
Conclusion: Oral immunotherapy is a promising treatment option for children with 
cow’s milk allergy. Before this treatment can be used in clinical practice, further studies 
are needed to answer remaining issues of the degree of protection, risk of reactions and 
best fit protocols.  
Keywords:  Children, immunotherapy, desensitization, cow’s milk hypersensitivity 
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Efficacy and Safety of Oral Immunotherapy in Children with Cow’s Milk Allergy 
BACKGROUND 
 Cow’s milk allergy is the most common food allergy affecting young children, 
with a prevalence of 2 to 4.5% of the general population.1 For the most part, cow’s milk 
(CM) allergy is thought to be temporary, with most children outgrowing the allergy by 
age 3.2 However, studies have shown that more than 19% of the children have ongoing 
CM allergy into their school age years, with 11% still allergic at age 8.3 Children with 
immunoglobulin E (IgE) mediated cow’s milk allergy can develop symptoms of urticaria, 
angioedema, rhinitis, conjunctivitis, gastrointestinal disorders and generalized 
anaphylaxis, usually occurring within 2 hours of exposure and this can be severe enough 
to cause a fatal outcome.4  
 Unfortunately, the current first line treatment of CM allergies is avoidance of all 
milk containing products and the use of self-injectable epinephrine pens as rescue 
medication.5 For most, let alone a young school age child, an elimination diet can be 
difficult and even impossible at times, especially with the number of processed foods 
made today, making accidental exposures more frequent and leaving children at high risk 
for severe and possibly fatal allergic reactions.6  
 A recent meta-analysis13 has shown promising results for the use of oral 
immunotherapy (OIT) for children suffering from IgE-mediated cow’s milk allergy. In 
general, the process of oral immunotherapy involves administering small, increasing 
doses of cow’s milk for a period of time until a maximum tolerance dose is met. This is 
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followed by a maintenance phase where that maximum tolerated dose is consumed daily. 
The actual mechanism behind immunotherapy is still unclear, but immunological changes 
involving immunoglobulins E and G4 have been used as markers,11 leading to the use of 
multiple names (oral desensitization, specific oral tolerance induction (SOTI) or oral 
immunotherapy) to describe the same concept. For most children, the higher the level of 
specific IgE to cow’s milk found in the serum at time of diagnosis, the less likely the 
child will come to spontaneously tolerate it over time11 and the more benefit from oral 
immunotherapy can be gained. Recent reviews,12-13 have described multiple studies that 
have used different protocols and study designs to evaluate the efficacy of oral 
immunotherapy in CM allergy. The results have ranged from minimal tolerance that will 
protect against accidental exposures to full tolerance with unrestricted diets. However, 
these results come with a price. Every time a child is purposely given cow’s milk during 
the OIT process, it puts them in harm’s way of a potentially serious allergic reaction. It is 
still unclear whether these results show temporary or long-term tolerance for these 
children. So the question remains, is OIT for cow’s milk allergy safe enough, and is the 
outcome worth the potential risk, to make OIT a part of routine clinical practice?  
 
METHODS 
An exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL, Web of Science and EBMR Multifile databases, using the 
keywords: children, immunotherapy, cow’s milk hypersensitivity and desensitization. 
The search was then specified to articles written in the English language and containing 
only human participants. Titles and abstracts were screened for information evaluating 
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the efficacy and safety issues of oral immunotherapy for children with cow’s milk 
hypersensitivities. All eligible articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE).14 
Inclusion Criteria 
Randomized Control Trials (RCTs) published after 2007, containing all relevant 
key terms and conducted on children of various ages (2-18 years-old) were included. 
Recent studies published in 2012 focusing on the relevant data above; that have not been 
critically appraised in previous reviews were also included. 
Exclusion criteria 
Randomized Control Trials before 2007 or conducted using children of a specific 
age were not included. Studies that evaluated data on other food allergies besides or as 
well as cow’s milk protein were not included. In addition, studies were not included if 
they did not address the safety issues surrounding the use of oral immunotherapy.  
  
RESULTS 
 The initial search yielded a total of 89 articles for screening. Once duplicates were 
removed, the search was reduced to 45 articles. After a thorough review of full texts for 
relevant data using the method previously stated, the search was narrowed to six 
randomized control trials. One RCT was excluded because it was conducted using only 2 
year-old children.15 A second RCT was excluded for using results for both cow’s milk 
and egg hypersensitivity16 and a third RCT was also excluded for using a narrow age 
range for children (ages 1-7) and for additionally conducting the study on children with 
egg hypersensitivity,17 leaving three articles that met inclusion criteria. An additional 
10 
 
search was performed on the remaining non-RCTs for studies published in 2012 
pertaining to the topic on hand, that were not already  included in recent reviews.12-13 One 
observational articles was found that met the inclusion criteria.10 Characteristics of the 
included studies can be found on Table 1. 
Longo et al Study 
 This randomized control trial7 evaluated the efficacy of specific oral tolerance 
induction (SOTI) in children with very severe cow’s milk allergy. The authors selected 
60 children from Trieste, Italy, aged 5-17 with milk-specific IgE levels greater than 85 
kUA/L (80% >100 kUA/L), a positive history of at least one severe allergic reaction 
when accidentally exposed to milk products (reaction classified as 4 and 5 on Clark’s 
classification18) and positive double-blind, placebo-controlled food challenge test to the 
lowest doses (0.8 mL of whole milk). The children were computer randomized into two 
groups: 30 children, the treatment group, were started on OIT immediately, while the 
remaining 30 children, control group, were kept on a milk-free, elimination diet and both 
groups were followed for one year. The OIT protocol had a rush phase and a slow 
increase phase. For the rush phase the children were admitted to the hospital for 10 days 
and received rapid increases in milk dosage. Doses were administered at 1-hour intervals 
on the first day and 2-hour intervals on days 2-10, with a maximum dose of 20 mL of 
whole milk on day 10. The slow increasing phase was performed at home with increasing 
dosages of 1mL every other day. Parents were instructed on proper protocol in case a 
reaction was to occur. The primary outcome was the ability of a child to tolerate 150 mL 
or more of whole cow’s milk as a single dose. SOTI was considered a failure if a child 
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did not tolerate at least 5 mL of whole cow’s milk in a single dose after one year or if the 
child discontinued SOTI due to severe side effects.7 
 After 1 year, in the treatment group, 11 (36%) of the 30 were able to consume a 
daily intake of 150 mL of whole cow’s milk or more, plus additional dairy products. 16 
(54%) were able to tolerate between 5-150 mL at a single dose and 3 (10%) dropped out 
of the study because of continuous allergic symptoms. In the control group, none of the 
children gained spontaneous improvement and were unable to tolerate 5 mL of whole 
cow’s milk at the end of the year. Adverse reactions in the SOTI group were very 
common, but mostly mild. A total of 5 children experienced an anaphylactic response 
requiring intramuscular (IM) epinephrine compared to none in the control group (NNH = 
7). In the control group, 6 (20%) children had mild reactions, none requiring IM 
epinephrine. The study found that specific IgE measured at 6 and 12 months showed a 
significant decrease in 15 (50%) of 30 in the SOTI group and IgE levels in the control 
group were essentially the same.7 
 Longo et al7 showed for the first time, that OIT can be effective in children 
suffering from a severe food allergy. In this study 36% of the children that underwent 
OIT were able to ingest cow’s milk and dairy products without restrictions after 1 year, 
compared to none in the control group (P<.001, NNT = 3). An additional 54% of children 
gained partial tolerance. Although they did not reach a unrestricted diet, the authors stress 
the importance of partial tolerance as the ability to still prevent accidental exposure to a 
small amount of cow’s milk (NNT = 2).7 
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 The authors found the limitations of the study to include the insufficient data to 
estimate the risk of fatal anaphylaxis during OIT compared to the risk of fatal 
anaphylaxis after accidental exposure in untreated children. It is also unclear as to 
whether the treatment offers a long-lasting immunity shift or if a daily maintenance dose 
is required. For these reasons, the authors recommend that SOTI be restricted until larger 
RCTs are conducted with longer follow-up; despite the promising results found.7 
Skripak et al Study 
 This study was the first randomized, double-blind, placebo-controlled trial8 to 
evaluate whether milk OIT is safe and efficient in desensitizing children with CM allergy. 
The authors enrolled 20 children from East Coast U.S. medical centers, aged from 6-17 
with a known history of IgE-mediated milk allergy (>0.35 kU/L), a positive skin prick 
test to milk extract and a positive double blinded, placebo controlled food challenge test 
to a cumulative amount of 2.5 g or less of milk protein. The children were randomized in 
a 2:1 ratio to a milk (treatment group=13) or placebo OIT (control group=7). The oral 
immunotherapy involved 3 phases: 1 day of build-up in-office with an initial dose 0.4 mg 
of milk protein and a final dose of 50 mg, an 8 week in-office dose increase to a 
maximum of 500 mg and then a daily maintenance dose at home for 3-4 months.8 
The study showed, 19 children completed the treatment, 12 in the active group 
and 7 in the placebo group. At the baseline double blinded placebo controlled food 
challenge both groups mean milk threshold dose was 40 mg. After oral immunotherapy 
the mean cumulative dose to cause a reaction in the treatment group was 5 140 mg (P = 
.002), while all patients in the placebo group still reacted at 40 mg (P = .0003). Four 
children in the treatment group were able to tolerate the entire 8 140 mg compared to 
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none in the control group (NNT = 4), while 8 other children were able to tolerate partial 
doses of 1 340-8 140 mg compared to none in the control group (NNT = 2). Milk specific 
IgE levels did not change significantly in either group, but the milk IgG levels increased 
significantly in the active group (P = .002). All the children in the active group 
experienced mild to moderate adverse reactions. Adverse reactions were more common 
in the treatment group than in the control group (35% to 1%) with most common being 
local and gastrointestinal reactions and 90% required no treatment. IM epinephrine had to 
be administered to 4 children of the treatment group compared to none in the control 
group (NNH = 4).8 
The authors found that milk OIT was effective in increasing the reaction threshold 
to milk in all children that were treated. However, limitations of the study noted by the 
authors include, the unclear concept as to whether the children are fully tolerant or simply 
temporarily desensitized and at risk for future reactions. Also, the authors note that 
allergic reactions with OIT were common and not optimal for therapy, even though most 
did not require treatment and those that did responded well to medications. The authors 
recommend the uncertainty of safety and long-term efficacy be further evaluated before 
OIT is considered for clinical practice.8 
Pajno et al Study 
 This randomized, single-blind, placebo controlled trial9 focused on establishing a 
patient-friendly desensitization protocol using a weekly up-dosing schedule. The authors 
enrolled 30 children, aged 4-13 years-old from allergy units of two hospitals in Italy, with 
IgE-mediated CM allergy confirmed by double blinded, placebo controlled food 
challenge test and positive skin prick test. The children were equally randomized to 
14 
 
desensitization with CM (treatment group) or soy milk (control group). Soy milk was 
used as the control, doses and treatment remained blinded to the investigators and 
physicians. However, the study was not blinded to the children and their parents because 
of the distinctive difference in taste between whole cow’s milk and soy milk. The oral 
immunotherapy protocol consisted of weekly outpatient visits, set-up for an 18-week 
regimen.  At weekly intervals, increasing amounts of CM (or soy milk) were given, 
starting with 1 drop of a 1:25 dilution and doubling every week in the clinic to reach a 
200 mL maximum at the end of the 18 weeks. A daily dose equal to the most recent 
weekly increased amount was given to each child at home.9    
 The study had 2 dropouts from the treatment group and 1 from the control group 
early in the protocol due to personal family reasons, leaving 13 children in the treatment 
group and 14 children in the control group. After the 18 weeks, 10 (77%) of the 13 
treatment children achieved full tolerance (200 mL) to CM, compared to none in the 
control group (NNT = 2). One child obtained partial tolerance (5-100 mL) to CM, 
compared to no children in the control group (NNT = 14). The authors state 3 children 
experienced severe reactions needing IM epinephrine in the treatment group, compared to 
no severe reactions among the control children (NNH = 5). The study found no 
significant changes in specific IgE levels following OIT treatment, but the study did note 
significant increases in specific IgG4 levels in children that were treated with OIT (P = 
.003). A follow-up at 6 months after completion of the study showed no clinical changes 
in the patients that continued to tolerate CM.9 
 Pajno et al9 argue that the proposed protocol is as safe and effective than 
previously mentioned studies, but more practical and patient-friendly because it does not 
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requiring hospitalization or long treatment periods. The authors mention that the 
significant increase in IgG4 levels shows an induced consistent immunologic change in 
children treated with OIT. However, the authors found the limitations of the study to 
include whether these immunologic changes correlate to a permanent or temporary 
desensitization. Pajno et al recommend the proposed outpatient weekly up-dosing 
protocol be the new choice of regimen for children with IgE-mediated CM allergies.9 
Sanchez-Garcia et al Study 
 This prospective open-label observational study10 focused on the efficacy of milk 
oral immunotherapy. The authors enrolled 105 children, aged 2-18, with IgE-mediated 
CM allergy (> 0.35 KU/L) from Nino Jesus Paediatric Hospital in Madrid, Spain. 
Children were not randomized to treatment and control groups and placebo was not used. 
The OIT protocol contained an induction phase and a maintenance phase. The induction 
phase consisted of increasing milk doses weekly in the clinic under medical supervision 
and continuing the tolerated dose at home daily, until a total dose of 200 mL of whole 
milk was met. Children were treated with a daily dose of antihistamines during the 
induction phase. Once the child achieved the daily intake of 200 mL of milk, the 
maintenance phase was started. The child was instructed to consume 200 mL or more of 
milk and dairy products daily until the end of the study.10  
 Of the 105 children in the study, 86 (81.9%) reached full tolerance of a daily dose 
of 200 mL of milk. 19 (19.1%) children did not meet the 200 mL daily intake and failed 
treatment due to either moderate or severe reactions or for personal reasons. The authors 
did not make it clear if any children achieved partial tolerance. The authors reported 3 
children had severe reactions requiring IM epinephrine (2.8%). The study did obtain 
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results showing a significant decrease in specific IgE to milk (P = 0.007) and casein (P = 
0.001) levels in children treated with OIT.10 
 The authors found the limitations of the study to include long-term follow-up for 
those children who were successful with OIT. The authors state it is still unclear as to 
which type of protocol (rush or slow up dose) gives maximum results with the fewest 
adverse reactions. The authors recommend that milk OIT should be implemented as a 
routine treatment for a child suffering from IgE-mediated CM allergy, but only by 
experienced allergist, specializing specifically in food allergy immunotherapy and where 
proper rescue medication is available. However, Sanchez-Gracia et al state, before this is 
possible further studies on accurate biomarkers to test response of OIT need to be done, 
as well as an international position paper.10  
DISCUSSION 
 The eligible studies7-10 found that children with cow’s milk allergies who received 
oral immunotherapy had a higher rate of achieving tolerance to cow’s milk than children 
who used elimination diet alone. The magnitude of the treatment effect was very large, 
however, the confidence behind this data is still somewhat lacking, as demonstrated by 
the moderate level of quality of evidence found (refer to Table 1).  
Clinical Relevance 
 The primary outcome when initiating oral immunotherapy is for the child to reach 
full tolerance to cow’s milk. Full tolerance by definition in the included articles is the 
ability to consume a minimum 150 mL of whole CM in a single dose with no allergic 
symptoms. The Longo et al7 study results yielded much lower tolerance rates compared 
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to other studies9-10  (36% vs. 80%). However, this is most likely due to the fact that their 
study only included children with severe cow’s milk allergy (>85 kUA/L) and therefore, 
less likely to become tolerant.11 In addition, when considering the children that gained 
partial tolerance (5-150 mL) the success rate increases to 27/30 (90%). This becomes a 
crucial point when considering children with life threatening CM allergy because even 
providing the smallest amount of protection can prevent against an accidental exposure 
and potentially save a life. The Skripak et al8 study also displayed lower tolerance rates 
(33%) than the other studies.9-10  This can be explained by the authors using an equivalent 
of 240 mL of whole cow’s milk as the maximum goal at the end of the induction phase 
compared to the 150 mL maximum used by most studies. In other words, 75% of the 
children were able to consume 125 mL of CM before having a reaction and overall, 100% 
of the children were able to achieve at least partial tolerance, which once again becomes a 
key aspect when considering accidental exposures.  
Pajno et al9 was the first to use a weekly up-dosing immunotherapy protocol and 
the most recent study by Sanchez-Garcia et al10 used a very similar set-up, requiring no 
hospitalization and only a time restraint average of 4.5 months. Both studies had over an 
80% full tolerance outcome, interpreted to mean that the “patient-friendly and easy-to-
use”9 regimen should be recommended as the preferred protocol of choice for OIT. 
Sanchez-Garcia et al10   also demonstrated that “high risk” children with severe cow’s 
milk allergy, that failed regular protocols, can still achieve full tolerance through the use 
of the slow up dose weekly protocol by extending the length of the induction phase.  
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In all the included studies,7-10 less than 20% of the children had to discontinue 
treatment due to severe allergic reaction. However, almost 100% of children in each trial 
did experience mild to moderate adverse reactions. Most of the reactions required no 
medication and future reactions in those children were minimized by decreasing the rate 
of oral desensitization. On average, the studies7-10 showed that one in four children treated 
with OIT would require use of IM epinephrine and therefore would have experienced a 
life threatening reaction during the therapy, compared to their control groups, where no 
child on elimination diet alone required IM epinephrine. This raises huge concern when 
considering OIT and whether it is worth putting children in high risk situations to prevent 
that same situation, which may or may not ever happen. On the other hand, if the choice 
was given, most parents would choose to have their children exposed to severe allergic 
reactions under direct supervision of a medical provider with all necessary rescue 
medications within arm’s reach, as opposed to a reaction occurring in some unknown 
location with no safe guards. In a recently published article, Barbi et al19 evaluates 
adverse effects during OIT. The study found that out of 192 children only 5 (2.6%) 
experienced a severe allergic reaction (Clark Scale 5)18 that required IM epinephrine. 
These results support the concept that even though adverse reactions are common and 
frequent during OIT, most are easily manageable. The concept of oral immunotherapy 
may appear simple to parents of milk allergic children and a process that they can easily 
do at home; however, each study stresses the dangers and the potential of a fatal outcome, 
surrounding the protocols. Oral immunotherapy needs to be treated with the up most 
respect and performed only under direct medical supervision to prevent accidental and 
unnecessary harm to a child.    
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Limitations of Study 
 The included studies7-10 offered promising results for the future of oral 
immunotherapy. However, the evidence supporting these results is of moderate quality 
(GRADE)14 because of serious limitations, imprecision and possible publication bias. 
Only one of the three included RCTs was double-blinded,8 (high quality) while the other 
two were single-blinded or contained no blinding7,9 (moderate quality) and the 
observational study had no randomization or control (low quality). In addition, there is 
variability across the studies, involving timing, differences in protocol and the 
appropriate markers for immunotherapy. Brozek et al,13 a systematic review and meta-
analysis for cow’s milk oral immunotherapy argues, that the evidence7-9 has very serious 
imprecisions due to very small sample sizes. The included studies7-10 were down-graded 
for this reason, but then upgraded because the magnitude of effect was large enough (RR 
= infinite) that a large sample size would not change the results. However, Brozek et al,13 
argued a strong point regarding the presence of publication bias. Although it cannot be 
proven, it is highly possible that studies containing high adverse reactions have remained 
unpublished, leading to weak evidence where anaphylactic shock is concerned. 
Recommendations for further studies include a standardized protocol, possibly 
similar to the patient-friendly regimen introduced by Pajno et al9 that focuses on 
minimizing allergic symptoms. Further studies should address the issue of “tolerance” vs. 
“desensitization” and whether a daily maintenance dose is required to maintain the 
acquired tolerance. Further double-blind, placebo-controlled RCTs need to be performed 
on large sample sizes, and adverse effects should be studied closely to minimize all bias.  
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CONCLUSION 
 Overall oral immunotherapy has a promising future as the treatment for children 
with cow’s milk allergies. Even if only partial tolerance is achieved the child and their 
parents will be able to live their lives without the constant fear of accidental exposure. 
The risk of experiencing a reaction during OIT protocols, although common, is much 
safer than the potential harm that can occur with an unexpected severe allergic response.  
Implications for the clinical practice is to recommend a standardized, patient-friendly, 
cost effective OIT protocol, for all children older than three with moderate to severe 
cow’s milk allergy, with a specific focus on young school age children, who are no 
longer under constant parental supervision and are therefore vulnerable to accidental 
exposure. Implications for the researchers are to conduct further studies to determine a 
standard protocol, that has maximum effects with the fewest adverse reactions and which 
is easy to perform and comply to, and to further evaluate the discussion of tolerance and 
desensitization to determine if a daily maintenance dose is required once tolerance is 
achieved. Researchers need to focus on discovering the mechanism behind oral 
immunotherapy, so a standardized biomarker can be used across studies to accurately 
display the effectiveness of the therapy. Until these further studies can be conducted and 
the true efficacy and safety of OIT determined, it is recommended that OIT for cow’s 
milk allergy only be used in scientific trials.   
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aNo blinding in the Longo et al study1 and the Pajno et al study3 was only single blinded. The observational trials had no randomization, control group or blinding 
bAll studies contain small sample sizes 
cRR> 2 in the RCTs 
dPublication bias likely due to possible misinterpretation of severity of reaction  
eNo participants in the controls that were able to tolerate the minimal amount of milk protein in food challenge
TABLE 1  Characteristics of Reviewed Studies, GRADE profile 
 
  
 
Quality Assessment  Summary of Findings 
Downgrade Criteria Upgrade Criteria  Number of Patients Effect 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Size of 
treatment effect 
Study 
Treatment 
(total) 
Placebo or 
no treatment 
(total) 
Relative 
Risk 
NNT/NNH 
Quality 
Importance 
Complete Tolerance to Cow’s Milk (>150 mL/day) 
Longo et al1 11/30 0/30 Infinitye 
NNT 
3 
Skripak et al2 4/12 0/7 Infinitye 
NNT 
4 
Pajno et al3 10/13 0/14 Infinitye 
NNT 
2 
4 
 
 
3 RCT 
1 
Observational 
 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely 
Very Largec 
Sanchez-Garcia 
et al4 
86/105 0 N/A 
NNT 
N/A 
Moderate Critical 
Partial Tolerance to Cow’s Milk (5-150 mL/day) 
Longo et al1 16/30 0/30 Infinitye 
NNT 
2 
Skripak et al2 8/12 0/7 Infinitye 
NNT 
2 
Paino et al3 1/13 0/14 Infinitye 
NNT 
14 
4 
3 RCT 
1 Observational 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely 
Very Largec 
Sanchez-Garcia 
et al4 
unclear 0 N/A 
NNT 
N/A 
Moderate Critical 
Anaphylaxis (use of IM epinephrine injection) 
Longo et al1 5/30 0/30 Infinitye 
NNH 
7 
Skripak et al2 4/12 0/7 Infinitye 
NNH 
4 
Pajno et al3 3/13 0/14 Infinitye 
NNH 
5 
4 
 
 
3 RCT 
1 Observational 
 
 
 
Serious 
limitationsa 
 
 
No serious 
indirectness 
 
 
Serious 
imprecisionb 
 
 
No serious 
inconsistencies 
 
 
Publication 
bias likelyd 
Not Large 
Sanchez-Garcia 
et al4 
3/105 0 N/A N/A 
Low Critical 
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